Breaking

Recovered Bayesian superyacht transferred to Sicilian port after being raised from seabed
State Department issues worldwide caution for US travelers following Trump’s Iran strikes
‘There is no one dirtier than Trump’: Some Iranians urge strong response after US strikes
Inside the Situation Room, where Trump and his national security team monitored ‘spectacular’ success on Iran
Thomas Massie says he feels ‘misled’ by Trump after Iran strikes: ‘He’s engaged in war’
JD Vance says Iranian nuclear program ‘substantially’ set back after ‘precise, surgical’ US strikes
Israeli President Herzog: Israel ‘not dragging’ US into war with Iran
Suicide bomber attack on church in Syria kills at least 20 people

Business
Politics
Investing
World
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Editor’s Picks: Silver Price Hits 13 Year High, Gold Takes a Breather

Tech 5: OpenAI/Microsoft Talks Get Tense, SoftBank Floats Arizona Robotics Hub

Top 5 Canadian Mining Stocks This Week: Royalties Inc. Jumps 183 Percent on Legal Win

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (1,654)
- Investing (5,061)
- Politics (7,882)
- World (6,360)

Disclaimer: usfinanceinsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest Posts

Copyright © 2025 usfinanceinsider.com | All Rights Reserved

Top

Business
Politics
Investing
World

Type above and press Enter to search. Press Esc to cancel.